Bambusa Therapeutics, Inc.
Bambusa Therapeutics, a clinical-stage biopharmaceutical company founded in March 2024, filed an S-1 to raise capital via an IPO on Nasdaq under the symbol "BBTX." The company is developing next-generation long-acting bispecific antibodies for immunology and inflammation, with lead candidates BBT001 (IL-4Rα/IL-31) in Phase 1/2 for atopic dermatitis and CSU, and BBT002 (IL-4Rα/IL-5) in Phase 1/2 for COPD, CRSwNP, and asthma. The filing does not yet specify the number of shares or price range.
- Lead candidate BBT001 (IL-4Rα/IL-31 bispecific) reported positive Phase 1 PoC data in atopic dermatitis: 82% EASI-50 and 64% EASI-75 at Week
- BBT001 demonstrated extended half-life supporting potential quarterly maintenance dosing and low immunogenicity with no conjunctivitis cases
- Second lead candidate BBT002 (IL-4Rα/IL-5 bispecific) showed ~29-day half-life and sustained dual biomarker effects in healthy volunteers
- Company plans multiple PoC readouts in H1 2027: 12-week AD data, bio-experienced AD data, CSU data, COPD data, and CRSwNP data
- Bambusa acquired assets from BioNTech Zhuhai and has worldwide rights to all four pipeline programs; two preclinical candidates (BBT003, BBT
Price data unavailable.
Bambusa is bringing a pipeline of four bispecific antibodies targeting the $200B+ I&I market to public markets, with early but compelling PoC data and a catalyst-rich H1 2027.
Enters the competitive I&I bispecific space alongside Apogee, Upstream Bio, and others targeting validated pathways. The global I&I market is projected to exceed $200 billion by 2030. BBT001 competes directly with Sanofi/Regeneron's Dupixent in AD.
Clinical-stage biotech with no approved products; all programs are Phase 1/2 with uncertain outcomes. The company has a limited operating history since March 2024 inception and will need substantial additional capital. PoC data is based on small sample sizes (17 patients for BBT001 4-week AD data).
Get filings like this before the market reacts.
Real-time SEC filing alerts, AI summaries, and a free daily digest — plus portfolio tracking that ties filings to your positions.